According to the UK’s Medicines & Healthcare products Regulatory Agency (MHRA), Ferring Pharmaceuticals has recalled multiple batches of Desmospray 0.1 mg/ml desmopressin, Aspire branded desmopressin 0.1 mg/ml, and Octim desmopressin 1.5 mg/ml nasal sprays “due to a lower volume of solution being observed in the bottles, and out of specification results for the content of the desmopressin acetate (active substance) and benzalkonium chloride (excipient).”
The Class 2 recall includes 14 batches of Desmospray distributed from October 2018 through April 2020; 7 batches of Aspire desmopressin distributed from Jul 2018 through June 2020; and 5 batches of Octim distributed from April 2018 to April 2020.
Update: Health Canada has also announced a recall of three lots of Ferring’s DDAVP desmopressin nasal spray “because the product may contain a higher than labelled dose of the active ingredient (desmopressin) and could pose an overdose risk.”
A number of other countries have issued recall alerts for Minirin desmopressin nasal spray.
Read the MHRA drug alert
Read the Health Canada recall alert
